AbbVie 4Q Revenues: $7.7 billion (+14%) 4Q Earnings: $52.0 million (earnings were $1.4 billion 4Q16) FY Revenues: $28.2 billion (+10%) FY Earnings: $5.3 billion (-11%) Comments: Global HUMIRA sales increased 14% in the quarter to $4.9 billion. Global IMBRUVICA sales were $708 million, up 39%. HCV franchise sales were up 63% to $510 million. Lupron sales were $224 million, up 2%. Creon sales were $235 million, up 11%. AndroGel sales were down 20% to $140 million, impacted by liability litig...